Bo Zhang

Bo Zhang

Auto-generated profile, based on publicly available information

Bo Zhang

Department of Surgery, Shengzhou People’s Hospital, Shaoxing, 312400, People’s Republic of China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HHHai-Feng Huang
Hai-Feng Huang
PJPiao-Piao Jin
Piao-Piao Jin
HYHan-Jin Yang
Han-Jin Yang
CZChun-Jun Zhang
Chun-Jun Zhang
XZXin Zhang
Xin Zhang
QHQi-Da Hu
Qi-Da Hu
Liver cancer is a common malignant disease in China, while the primary hepatic neuroendocrine tumor (PHNET) is extremely rare presented with various manifestations. We herein describe an interesting PHNET case, which was clinically diagnosed as hepatocellular carcinoma (HCC) based on strong clinical evidence and the national guideline, but confirmed to be PHNET by pathology. A 42-year-old Chinese male was admitted for persistent upper abdominal pain, and CT scan revealed a huge liver tumor in the left lobe. The tumor presented attributes of tumor rupture, portal vein tumor thrombus, elevated serum AFP level, background hepatitis B virus infection history, and radiological features mimicking typical HCC. After left semi-hepatectomy was performed for curative treatment of the primary “HCC”, the pathology demonstrated the correct diagnosis be poorly differentiated neuroendocrine carcinoma (NEC). The immunohistochemistry assays showed positive neuroendocrine markers of CgA and Syn and negative HCC markers of Hep Par 1 and GPC3, ruling out concurrent HCC. This case and literature review suggest that in spite of rare incidence, PHNET should be considered as a possible diagnosis when lacking a confirmative pathology result, even when sufficient evidence of typical presentation exist to establish the clinical diagnosis of HCC.

1 March 2014
Verified
Journal Article
Open access
PDF file
XZXiang Zhu
Xiang Zhu
HLHongwei Bran Li
Hongwei Bran Li
BCBaoshan Cao
Baoshan Cao
CLChen Liu
Chen Liu
LLLiang Li
Liang Li
BZBo Zhang
Bo Zhang
Background and objective The fusion (rearrangement) of anaplastic lymphoma kinase (ALK) gene has been identified as an import factor to the tumorigenesis and development of lung cancer. ALK tyrosine kinase inhibitors (ALK-TKIs) have been proved to have good effects to ALK positive lung cancers. The increasement of the relevance ratio of ALK will be very important to patients. The aim of this study is to investigate the clinical pathological features of ALK positive lung cancer, and the roles of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in screening and confirming the ALK positive cases in the testing flow of ALK. Methods IHC analysis of ALK in tumor specimens was performed on 525 lung cancer patients. 34 cases among them were confirmed by FISH. Results The positive incidence of ALK by IHC was 5.14% (27/525). The ALK positive patients were significantly younger than ALK negative patients (P<0.05), and femal was predominant (P<0.05). The proportion of solid predominant adenocarcinoma was significantly higher in ALK positive patients (P<0.05). While acinar and lepidic predominant adenocarcinoma were significantly lower in ALK positive patients (P<0.05). FISH was applied in 34 cases. The coincidence rate was increased with the increasement of positive intensity of IHC staining. All the IHC positive cases with or without EGFR mutation must be confirmed by FISH. Conclusion IHC is a reliable detection method to screening the ALK in lung cancer, and then enhance the relevance ration. To make a definite diagnosis of ALK positive lung cancer, FISH is a significant detection method. DOI: 10.3779/j.issn.1009-3419.2014.03.08

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
FHFang Hu
Fang Hu
BZBo Zhang
Bo Zhang
CLChanghui Li
Changhui Li
JXJianlin Xu
Jianlin Xu
HWHuimin Wang
Huimin Wang
XZXueyan Zhang
Xueyan Zhang
Introduction: Lung cancer diagnosed solely with the presence of intrathoracic metastases is classified as M1a. However, intrathoracic metastases can be further divided into different patterns. The objective of our study was to analyze the differences in survival between the different metastatic patterns of intrathoracic metastases in lung adenocarcinoma patients who have epidermal growth factor receptor (EGFR) mutations.

1 July 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
BZBo Zhang
Bo Zhang
QHQida Hu
Qida Hu
JYJiajie Yu
Jiajie Yu
JWJunsen Wang
Junsen Wang
HYHanjin Yang
Hanjin Yang
YZYun Zhang
Yun Zhang
Immunohistochemistry (IHC) is a vital tool to distinguish tumor metastases from primary lesions in addition to morphologic analysis. In this study, a 64-year-old female with a past surgical history of lung adenocarcinoma 11 years ago was presented with recurrence of liver nodular lesions after multiple surgical procedures, including the Whipple procedure for pancreatic head adenocarcinoma and cytoreductive surgery for liver metastasis. Liver biopsy and review of the previous specimens, based on IHC analyses, suggested heterochronous metastases of lung adenocarcinoma to the digestive systems in a long-time span, instead of primary pancreatic adenocarcinoma. This case demonstrates the potential for misdiagnoses from morphologic analysis alone and suggests the necessity of IHC analyses to avoid misjudgment on tumor phenotypes, when a previous oncologic history is presented.